Clinical trials: Metastatic Squamous Cell Carcinoma
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
- Trial name
- NCT07115043
- Testing
- AZD6750, rilvegostomig
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Lung Cancer, Metastatic Cancer
Positron Emission Tomography and Computed Tomography in Planning Treatment for Patients Undergoing 3-Dimensional Conformal Radiation Therapy for Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery. ICORG 06-35
RATIONALE: Diagnostic procedures, such as positron emission tomography and computed tomography, may help learn the extent of disease and allow doctors to plan 3-dimensional conformal radiation therapy.
- Trial name
- NCT00958321
- Testing
- computed tomography, 3-dimensional conformal radiation therapy, fludeoxyglucose F 18
- Where
- Ireland
- Volunteers
- 40 people
- Sponsor
- Cancer Trials Ireland
Neoplasms, Head and Neck
Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
This study is being conducted to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in adult subjects with squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT00725764
- Testing
- GSK1363089 (foretinib)
- Where
- 11 sites in United States
- Volunteers
- 14 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
This multicentre, open-label, Phase 1b/2 study is designed as a 2 part study consisting of a dose-escalation, safety run-in Part A and a dose-expansion Part B
- Trial name
- NCT02499328
- Testing
- AZD9150, MEDI4736, AZD5069
- Where
- 44 sites in United States, Belgium and 4 more
- Volunteers
- 340 people
- Sponsor
- AstraZeneca
Head and Neck Squamous Cell Carcinoma
Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The investigators hypothesize that inhibition of angiogenesis and PD-1 will be more effective than inhibition of PD-1 alone. The first step in pursuing proof of this hypothesis is to establish the safety and feasibility of…
- Trial name
- NCT03650764
- Testing
- Ramucirumab, Pembrolizumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Washington University School of Medicine
Non-Small Cell Lung Cancer, c-MET
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab…
- Trial name
- NCT07155187
- Testing
- Telisotuzumab Adizutecan, Standard of Care, Osimertinib
- Where
- 117 sites in United States, Australia and 18 more
- Volunteers
- 490 people
- Sponsor
- AbbVie
Recessive Dystrophic Epidermolysis Bullosa
Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC
This pilot trial studies how rigsertib sodium works in treating patients with Recessive Dystrophic Epidermolysis bullosa (RDEB) with locally advanced Squamous Cell Carcinoma (SCC).
- Trial name
- NCT04177498
- Testing
- Rigosertib Sodium, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Thomas Jefferson University
Lip, Lip Cancer
T1 Squamous Cell Carcinomas of the Lip
The purpose of this study is to investigate the risk of recurrence and metastasis in patients treated with different surgical margins (5mm vs 10mm) for a T1 squamous cell carcinoma of the lip.
- Conditions
- Lip, Lip Cancer, Lip SCC, Squamous Cell Carcinoma
- Trial name
- NCT05610293
- Where
- 3 sites in Netherlands
- Volunteers
- 300 people
- Sponsor
- Maastricht University Medical Center
Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma
A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma
To evaluate the efficacy and safety of TQB2618 injection combined with Penpulimab and chemotherapy in the first-line treatment of relapsed/metastatic head and neck squamous cell carcinoma compared to Penpulimab combined…
- Trial name
- NCT05783921
- Testing
- TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin
- Where
- 12 sites in China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-Small Cell Lung Cancer
Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer
The main objective of this study is to determine recommended phase II dose and safety of tetrathiomolybdate (TM) in combination with carboplatin and pemetrexed in chemo-naive metastatic or recurrent non-squamous non-small cell…
- Trial name
- NCT01837329
- Testing
- Tetrathiomolybdate
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Rochester
Non-small Cell Lung Cancer
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults with the following…
- Trial name
- NCT03515837
- Testing
- pembrolizumab, pemetrexed, carboplatin
- Where
- 158 sites in United States, Australia and 15 more
- Volunteers
- 492 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Squamous Carcinoma Cell
A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy
Effective later-line treatment options remain an unmet medical need for patients with advanced esophageal squamous cell carcinoma (ESCC) whose disease has progressed after prior immunotherapy, particularly given the widespread…
- Trial name
- NCT07688291
- Testing
- PD-1/IL-2α-bias bispecific antibody fusion protein
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Beijing GoBroad Hospital
Lung Cancer, Non Small Cell Lung Cancer
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
The purpose of this study is to find out what effects (good and/or bad) Pirfenidone combined with standard first-line chemotherapy will have on you and non-small cell lung cancer (NSCLC).
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Advanced Cancer, Metastatic Lung Cancer
- Trial name
- NCT03177291
- Testing
- Pirfenidone, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Head and Neck Squamous Cell Carcinoma
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent…
- Trial name
- NCT06496178
- Testing
- Petosemtamab, Investigator's Choice
- Where
- 193 sites in United States, Argentina and 22 more
- Volunteers
- 621 people
- Sponsor
- Genmab
Carcinoma, Non-Small-Cell Lung
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
The primary purpose of this study is to determine the safety and tolerability of the combination of bemcentinib with chemo-immunotherapy (CIT) to identify the recommended phase 2 dose (RP2D) when administered as first line (1L)…
- Trial name
- NCT05469178
- Testing
- Bemcentinib, Pembrolizumab, Pemetrexed
- Where
- 34 sites in United States, France and 5 more
- Volunteers
- 26 people
- Sponsor
- BerGenBio ASA
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
This phase II trial studies how well low dose, reduced frequency nivolumab works in treating patients with cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT07576725
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- Uganda
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Penile Squamous Cell Carcinoma Stage IV
Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)
Penile cancer is an uncommon disease, with devastating physical and psychological effects on patients. Penile carcinoma even in advanced stages is responsive to several chemotherapeutic agents.
- Trial name
- PAZOPEN-SOGUG (NCT02279576)
- Testing
- Pazopanib, Paclitaxel
- Where
- 8 sites in Spain
- Volunteers
- 4 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Head and Neck Squamous Cell Carcinomas, Solid Tumors
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
This Phase II study is a clinical trial exploring the efficacy and safety of BL-M08D1 for injection in patients with recurrent or metastatic squamous cell carcinoma of the head and neck and other solid tumors.
- Trial name
- NCT07788950
- Testing
- BL-M08D1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Head and Neck Cancer
Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00573989
- Testing
- erlotinib hydrochloride, pemetrexed disodium, quality-of-life assessment
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Wake Forest University Health Sciences
Head and Neck Cancer
Studying Biomarkers in Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on E1302 Trial
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01619618
- Testing
- mutation analysis, polymerase chain reaction, polymorphism analysis
- Volunteers
- 183 people
- Sponsor
- Eastern Cooperative Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.